Q1 Earnings Forecast for VIR Issued By Leerink Partnrs

Vir Biotechnology, Inc. (NASDAQ:VIR) – Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Vir Biotechnology in a research report issued to clients and investors on Sunday, January 12th. Leerink Partnrs analyst R. Ruiz forecasts that the company will post earnings of ($1.09) per share for the quarter. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($3.92) per share. Leerink Partnrs also issued estimates for Vir Biotechnology’s FY2025 earnings at ($3.80) EPS, FY2026 earnings at ($3.05) EPS, FY2027 earnings at ($2.15) EPS and FY2028 earnings at ($0.60) EPS.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.05) by ($0.51). Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The business had revenue of $2.38 million during the quarter, compared to the consensus estimate of $5.54 million. During the same quarter last year, the firm posted ($1.22) earnings per share. Vir Biotechnology’s revenue was down 9.8% compared to the same quarter last year.

Several other research analysts have also recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 price target on shares of Vir Biotechnology in a report on Friday, January 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 target price on shares of Vir Biotechnology in a report on Wednesday, November 20th. Leerink Partners increased their price target on Vir Biotechnology from $18.00 to $20.00 and gave the company an “outperform” rating in a research report on Monday. JPMorgan Chase & Co. boosted their price objective on Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a report on Thursday, January 9th. Finally, Barclays decreased their target price on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Monday, November 4th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Vir Biotechnology presently has an average rating of “Moderate Buy” and an average price target of $34.83.

Vir Biotechnology Price Performance

VIR stock opened at $10.05 on Wednesday. The firm has a market cap of $1.38 billion, a PE ratio of -2.56 and a beta of 0.51. Vir Biotechnology has a 12 month low of $6.56 and a 12 month high of $14.45. The firm has a 50 day simple moving average of $8.28 and a 200 day simple moving average of $8.39.

Insider Activity at Vir Biotechnology

In other Vir Biotechnology news, Director Vicki L. Sato sold 10,960 shares of Vir Biotechnology stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total transaction of $137,219.20. Following the transaction, the director now owns 1,312,391 shares of the company’s stock, valued at $16,431,135.32. The trade was a 0.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders have sold 14,786 shares of company stock valued at $170,172. Company insiders own 15.60% of the company’s stock.

Institutional Trading of Vir Biotechnology

A number of hedge funds have recently made changes to their positions in the stock. Blue Trust Inc. increased its stake in shares of Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock worth $30,000 after acquiring an additional 2,351 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of Vir Biotechnology in the third quarter worth $56,000. Magnetar Financial LLC bought a new position in shares of Vir Biotechnology during the 2nd quarter worth about $95,000. Quest Partners LLC raised its holdings in Vir Biotechnology by 142.1% in the 2nd quarter. Quest Partners LLC now owns 12,695 shares of the company’s stock valued at $113,000 after acquiring an additional 7,452 shares in the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Vir Biotechnology in the second quarter valued at $119,000. 65.32% of the stock is owned by hedge funds and other institutional investors.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).